Keywords
insulin
hypoglicemya
drug utilization
drug prescription
pharmacoepidemiology
How to Cite
Abstract
Context: Type 2 diabetes mellitus is a disease with global distribution and increasing prevalence. Different types of insulin are used in its treatment and, of these, the ultra-long-acting analogues are the most expensive.
Objective: To evaluate the prescription-indication of ultra-long-acting insulins based on the recommendations of their place in therapy, in patients with type 2 diabetes of a Colombian health service provider institution, from January to December 2021.
Methodology: Pharmacoepidemiological, descriptive and cross-sectional study, which included 309 records of patients prescribed with an ultra-long-acting insulin in the established period. The variables analyzed were sex, age, education, body mass index, time since diagnosis of type 2 diabetes mellitus, history of hypoglycemia, caregiver dependency, comorbidities, medications used, and percentage of glycosylated hemoglobin. Statistical tests such as Chi square and binary logistic regression were applied, stablishing as statistically significant difference p value <0,05 (IC 95%).
Results: 51.5% of the patients were male, the median age was 60 years (IQR 12.0) and 33.3% had a history of hypoglycemia. There was no statistically significant relationship between the prescription of these insulins with the variables that promote hypoglycemia. Insulin degludec was more prescribed.
Conclusions: Potentially, ultra-long-acting insulins are being used without considering the clinical profile of each patient and the conditions in which they offer an additional benefit by reducing hypoglycemia, which suggests an opportunity to improve their use.
References
Reyes-Sanamé F, Pérez-Álvarez M, Alfonso-Figueredo E, Ramírez-Estupiñán M, Jiménez-Rizo Y. Tratamiento actual de la diabetes mellitus tipo 2. Correo Científico Médico. 2016;20(1): https://revcocmed.sld.cu/index.php/cocmed/article/view/2194
Federación Mexicana de Diabetes, AC. Atlas IDF 10º edición-2021. 2021. https://fmdiabetes.org/atlas-idf-10o-edicion-2021/
Fernández R. Diabetes-Datos estadísticos. Statista. 2023. https://es.statista.com/temas/3526/diabetes/#topicOverview
Vargas-Uricoechea H, Casas-Figueroa LA. Epidemiología de la diabetes mellitus en Sudamérica: la experiencia de Colombia. Clin Investig Arterioscler. 2016;28(5):245-256. https://doi.org/10.1016/j.arteri.2015.12.002
Bautista N. Tres de cada 100 colombianos tienen diabetes. Bogotá: Ministerio de Salud; 2020. https://www.minsalud.gov.co/Paginas/Tres-de-cada-100-colombianos-tienen-diabetes.aspx
Mordor Intelligence. Tamaño del mercado de insulina basal y análisis de acciones, tendencias y pronósticos de crecimiento (2023-2028). Telangana, India. 2022. https://www.mordorintelligence.com/es/industry-reports/global-basal-insulin-long-acting-insulin-market-2012-2024
de Luis DA, Romero E. Análogos de insulina: Modificaciones en la estructura, consecuencias moleculares y metabólicas. Semergen. 2013;39(1):34–40. https://doi.org/10.1016/j.semerg.2012.04.010
Villarreal Ríos E, Romero Zamora KG, Vargas Daza ER, Galicia Rodríguez L, Martínez González L, Ramos López JM. Coste-efectividad del uso de esquemas de tratamiento farmacológico en pacientes con diagnóstico de diabetes mellitus tipo 2. Rev Clin Med Fam. 2012;5(3):158-165. https://doi.org/10.4321/S1699-695X2012000300003
Bejarano-Roncancio JJ, Almarza-labarca JC, Veloza-Naranjos AL. Análogos de insulina: relevancia clínica y perspectivas futuras. Rev Fac Med. 2012;60(4):333-341. http://www.scielo.org.co/pdf/rfmun/v60n4/v60n4a10.pdf
Yale JF, Aroda VR, Charbonnel B, Sinclair AJ, Trescoli C, Cahn A, et al. Glycaemic control and hypoglycaemia risk with insulin glargine 300?U/mL versus glargine 100?U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes Metab. 2020;46 (2):110-118. https://doi.org/10.1016/j.diabet.2018.10.002
Home PD, Bolli GB, Mathieu C, Deerochanawong C, Landgraf W, Candelas C, et al. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes. Diabetes Obes Metab. 2015;17(1):15-22. https://doi.org/10.1111/dom.12329
American Diabetes Association. Standards of medical care in diabetes. 2022; 45(1): S21–226. https://diabetesjournals.org/care/issue/45/Supplement_1
Madenidou AV, Paschos P, Karagiannis T, et al. Comparative benefits and harms of basal insulin analogues for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2018;169(3):165-174. https://doi.org/10.7326/M18-0443
Wysham C, Bhargava A, Chaykin L, De La Rosa R, Handelsman Y, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes the SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45-56. https://doi.org/10.1001/jama.2017.7117
Yu NC. Nocturnal glycemic control with new insulin glargine 300 U/mL. Adv Med. 2019;2019:8587265. https://doi.org/10.1155/2019/8587265
Cheng A, Bailey TS, Mauricio D, Roussel R. Insulin glargine 300 U/mL and insulin degludec: a review of the current evidence comparing these two second-generation basal insulin analogues. Diabetes Metab Res Rev. 2020;36(7):e3329. https://doi.org/10.1002/dmrr.3329
Lipska KJ, Parker MM, Moffet HH, Huang ES, Karter AJ. Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes. JAMA. 2018;320(1):53-62. https://doi.org/10.1001/jama.2018.7993
Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (edition 2). Diabetes Care. 2014;37(12):3235-3243. https://doi.org/10.2337/dc14-0990
Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35(12):2464-2471. https://doi.org/10.2337/dc12-1205
Figueiras Guzmán A, Caamaño Isoma F, Gestal Otero JJ. Metodología de los estudios de utilización de medicamentos en atención primaria. Gaceta Sanitaria. 2000;14(3):7-19. https://dialnet.unirioja.es/servlet/articulo?codigo=6388131
Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, et al. More similarities than differences testing insulin glargine 300 Units/mL versus insulin degludec 100 Units/mL in insulin?naive type 2 diabetes: the randomized head?to?head BRIGHT trial. Diabetes Care. 2018;41(10):2147-2154. https://doi.org/10.2337/dc18-0559
Philis-Tsimikas A, Klonoff DC, Khunti K, Bajaj HS, Leiter LA, Hansen M V., et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head conclude trial. Diabetologia. 2020;63(4):698-710. https://doi.org/10.1007/s00125-019-05080-9
Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, et al. Patient-level meta-analysis of the edition 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes, Obes Metab. 2015;17(9):859-867. https://doi.org/10.1111/dom.12485
Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723-732. https://doi.org/10.1056/NEJMoa1615692
Revista de la Asociación Latinoamericana de Diabetes. Guías ALAD sobre el Diagnóstico, Control y Tratamiento de la Diabetes Mellitus Tipo 2 con Medicina Basada en Evidencia. Barcelona: ALAD; 2019. https://www.revistaalad.com/guias/5600AX191_guias_alad_2019.pdf
Di Lorenzi Brozzone RM. Bruno L, Pandolfi M. Javiel G, Goñi M. Hipoglucemia en pacientes diabéticos. Rev urug med interna. 2017;3:51-60. http://www.scielo.edu.uy/pdf/rumi/v2n3/2993-6797-rumi-2-03-00051.pdf
Goldberg Eliaschewitz F, Barreto T. Concepts and clinical use of ultra-long basal insulin. Vol. 8, Diabetol metab syndr. 2016;8:2. https://doi.org/10.1186/s13098-015-0117-1
Philis-Tsimikas A, Klonoff DC, Khunti K, Bajaj HS, Leiter LA, et al. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head conclude trial. Diabetologia. 2020;63(4):698-710. https://doi.org/10.1007/s00125-019-05080-9
Aschner P. Epidemiología de la diabetes en Colombia. Avances en diabetología. 2010;26(2):95-100. https://doi.org/10.1016/S1134-3230(10)62005-4
Estrada Vázquez LG. Asociación de la hipertensión arterial, descontrol glucémico y dislipidemia con la presencia de retinopatía diabética en pacientes con diabetes tipo 2 [tesis doctoral]. México: Universidad Nacional Autónoma de México; 2016. https://es.studenta.com/content/111302235/asociacion-de-la-hipertension-arterial-descontrol-glucemico-y-dislipidemia-con-l
Pauza AG, Thakkar P, Tasic T, Felippe I, Bishop P, et al. GLP1R attenuates sympathetic response to high glucose via carotid body inhibition. Circ Res. 2022;130(5):694-707. https://doi.org/10.1161/CIRCRESAHA.121.319874
Instituto Biomédico IBQUAES. Aspectos genéticos de la diabetes y la hipercolesterolemia. Valencia: IBQUAES; 2018. https://ibquaes.com/blog/genetica-diabetes-e-hipercolesterolemia/
Hauber A, Gale EAM. The market in diabetes. Diabetologia. 2006;49(2):247-452. https://doi.org/10.1007/s00125-005-0108-0
Anari R, Amani R, Veissi M. Obesity and poor glycemic control in patients with type 2 diabetes. Int J Res Med Sci. 2016;4(2):584-588. https://doi.org/10.18203/2320-6012.ijrms20160320
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo